tradingkey.logo
๎™ผ
tradingkey.logo
๎™๊ฒ€์ƒ‰
๎™

Viking Therapeutics Inc

VKTX
๎˜ญ๊ด€์‹ฌ ๋ชฉ๋ก์— ์ถ”๊ฐ€
27.280USD
+0.420+1.56%
์ข…๊ฐ€ย 10-30 16:00๏ผˆET๏ผ‰
3.47B์‹œ๊ฐ€์ด์•ก
์†์‹คP/E TTM
์žฅ์™ธ ๊ฑฐ๋ž˜ย 17:40ย (ET)27.070USD-0.245-0.90%

VKTX ์žฌ๋ฌด ๋ฐ์ดํ„ฐ

์Šค๋งˆํŠธํ•œ ํˆฌ์ž์ž๋ฅผ ์œ„ํ•ด ์„ค๊ณ„๋œ ์˜ฌ์ธ์› ๋ฐ์ดํ„ฐ ๋Œ€์‹œ๋ณด๋“œ๋ฅผ ํ†ตํ•ด Viking Therapeutics Inc์˜ ์žฌ๋ฌด ๋ฐ์ดํ„ฐ๋ฅผ ํ™•์ธํ•˜์„ธ์š”. ๋ณต์žกํ•œ ์žฌ๋ฌด์ œํ‘œ๋ฅผ ์‚ฌ์šฉ์ž ์ •์˜ ๊ฐ€๋Šฅํ•œ ๋ทฐ๋กœ ๊ตฌ์„ฑํ•˜์—ฌ ์žฌ๋ฌด ๋ถ„์„์„ ์ œ๊ณตํ•ฉ๋‹ˆ๋‹ค. ์ตœ์‹  ์—ฐ๊ฐ„ ์žฌ๋ฌด ๋ณด๊ณ ์„œ์— ์ ‘๊ทผํ•˜๊ฑฐ๋‚˜, ์†์ต๊ณ„์‚ฐ์„œ, ์žฌ๋ฌด์ƒํƒœํ‘œ, ํ˜„๊ธˆ ํ๋ฆ„ํ‘œ๋ฅผ ์‚ฌ์šฉํ•˜์—ฌ ๋ถ„๊ธฐ๋ณ„ ์„ฑ๊ณผ๋ฅผ ๋ถ„์„ํ•˜์„ธ์š”. ์‹ค์‹œ๊ฐ„ ์žฌ๋ฌด ์ง€ํ‘œ๋ฅผ ์†๋์—์„œ ํ™•์ธํ•  ์ˆ˜ ์žˆ์–ด ํšŒ์‚ฌ์˜ ์‹œ์žฅ ๊ฑด์ „์„ฑ์„ ์‹œ๊ฐ„์— ๋”ฐ๋ผ ๊ทธ ์–ด๋А ๋•Œ๋ณด๋‹ค ์‰ฝ๊ฒŒ ๋ชจ๋‹ˆํ„ฐ๋งํ•  ์ˆ˜ ์žˆ์Šต๋‹ˆ๋‹ค.
ํ•ต์‹ฌ ์žฌ๋ฌด ๋น„์œจ
์‹œ๊ฐ€์ด์•ก
3.47B
๋ฐฐ๋‹น ์ˆ˜์ต๋ฅ 
0.00
P/E TTM
-6.57
์ฃผ๋‹น์ˆœ์ด์ต
-4.15
์ˆ˜์ต
0.00
์ˆœ์ด์ต
-109.96M
ROE
-70.04%
ROA
-64.04%
Viking Therapeutics Inc ์‹ค์  ๋ฐœํ‘œ์ผ๎˜
์ตœ์‹  ์ถœ์‹œ
Oct 28, 2026
EPS / ์˜ˆ์ƒ
-1.55/-1.07
์ˆ˜์ต / ์˜ˆ์ƒ
0.00/0.00

์žฌ๋ฌด์ œํ‘œ ์š”์•ฝ

๋ถ„๊ธฐ๋ณ„๎˜ฎ
๋ถ„๊ธฐ๋ณ„+์—ฐ๊ฐ„
๋ถ„๊ธฐ๋ณ„
์—ฐ๊ฐ„
FY2026Q3
FY2026Q2
FY2026Q1
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021Q4
์žฌ๋ฌด ์ง€ํ‘œ
EPS
-91.98%-1.55
-88.34%-1.10
-236.48%-1.37
-334.80%-1.38
-259.46%-0.81
-190.07%-0.58
-53.98%-0.41
-29.18%-0.32
0.37%-0.22
-3.81%-0.20
-6.08%-0.26
3.60%-0.25
---0.23
---0.19
---0.25
---0.26
---0.64
----
----
----
์ˆ˜์ต
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
์ˆœ์ด์ต
-101.78%-183.19M
-95.27%-128.02M
-246.98%-158.32M
-345.16%-157.66M
-264.02%-90.79M
-194.66%-65.56M
-66.80%-45.63M
-43.94%-35.42M
-10.68%-24.94M
-15.73%-22.25M
-40.06%-27.36M
-25.80%-24.61M
-42.86%-22.53M
-10.29%-19.23M
-21.29%-19.53M
-58.30%-19.56M
-19.10%-15.77M
-13.33%-17.43M
-14.94%-16.10M
-12.86%-12.36M
๋ถ€์ฑ„๋น„์œจ
--25.65%
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
์ˆ˜์ต
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
์˜์—… ์ด์ต
-89.84%-187.11M
-77.81%-132.60M
-195.89%-164.13M
-256.28%-164.74M
-169.62%-98.56M
-118.99%-74.57M
-62.79%-55.47M
-57.89%-46.24M
-34.08%-36.56M
-43.45%-34.05M
-65.91%-34.07M
-44.38%-29.29M
-68.34%-27.27M
-34.65%-23.74M
-26.42%-20.54M
-62.13%-20.28M
-20.84%-16.20M
-13.45%-17.63M
-14.18%-16.25M
-11.04%-12.51M
์ˆœ์ด์ต
-101.78%-183.19M
-95.27%-128.02M
-246.98%-158.32M
-345.16%-157.66M
-264.02%-90.79M
-194.66%-65.56M
-66.80%-45.63M
-43.94%-35.42M
-10.68%-24.94M
-15.73%-22.25M
-40.06%-27.36M
-25.80%-24.61M
-42.86%-22.53M
-10.29%-19.23M
-21.29%-19.53M
-58.30%-19.56M
-19.10%-15.77M
-13.33%-17.43M
-14.94%-16.10M
-12.86%-12.36M
์œ ๋™์ž์‚ฐ
31.72%973.00M
-37.42%517.56M
-29.77%608.21M
-21.12%715.60M
-21.13%738.70M
-12.55%827.02M
-10.38%866.02M
147.05%907.22M
145.65%936.65M
136.80%945.72M
546.52%966.34M
119.84%367.23M
130.89%381.30M
122.04%399.37M
-22.68%149.47M
-20.66%167.04M
-26.37%165.15M
-24.32%179.86M
-22.64%193.30M
-17.80%210.53M
์œ ๋™ ๋ถ€์ฑ„ ์ด๊ณ„
413.66%133.90M
242.89%109.66M
443.22%106.33M
179.67%76.67M
1.49%26.07M
27.45%31.98M
-40.28%19.57M
43.26%27.41M
91.61%25.68M
86.18%25.09M
109.43%32.77M
-12.81%19.14M
-4.67%13.40M
-9.32%13.48M
38.88%15.65M
150.02%21.95M
23.85%14.06M
15.48%14.86M
-12.76%11.27M
-27.63%8.78M
์ด ์ž์‚ฐ
32.15%977.17M
-36.96%521.90M
-29.84%608.24M
-21.20%715.73M
-21.16%739.41M
-12.57%827.85M
-10.39%866.99M
146.50%908.32M
145.10%937.89M
136.30%946.84M
541.19%967.52M
118.65%368.49M
129.58%382.66M
120.76%400.69M
-22.63%150.90M
-20.00%168.53M
-25.75%166.68M
-23.69%181.51M
-22.03%195.03M
-17.87%210.66M
๋ถ€์ฑ„ ์ด๊ณ„
1372.68%388.57M
250.67%113.58M
429.64%106.33M
173.39%76.67M
-0.21%26.39M
25.26%32.39M
-40.30%20.07M
39.72%28.04M
83.32%26.44M
77.38%25.86M
99.80%33.63M
-13.51%20.07M
-6.33%14.42M
-10.44%14.58M
31.92%16.83M
164.38%23.21M
35.63%15.40M
26.47%16.28M
-1.22%12.76M
-27.80%8.78M
์ž๋ณธ ์ด๊ณ„
-17.45%588.60M
-48.67%408.32M
-40.74%501.92M
-27.40%639.06M
-21.77%713.03M
-13.63%795.46M
-9.31%846.92M
152.65%880.28M
147.51%911.45M
138.52%920.98M
596.60%933.89M
139.76%348.42M
143.41%368.24M
133.68%386.12M
-26.45%134.06M
-28.02%145.32M
-29.01%151.28M
-26.56%165.23M
-23.17%182.27M
-17.38%201.88M
์ˆœ์˜์—…์ด์ต
-47.01%-138.19M
-165.98%-125.17M
-117.80%-113.98M
-173.53%-85.29M
-328.03%-94.00M
-65.05%-47.06M
-753.13%-52.33M
-76.76%-31.18M
-11.72%-21.96M
-149.35%-28.51M
75.11%-6.13M
-61.45%-17.64M
-45.63%-19.66M
14.93%-11.44M
-134.03%-24.64M
11.53%-10.93M
-23.55%-13.50M
-0.06%-13.44M
3.18%-10.53M
-125.12%-12.35M
์ˆœํˆฌ์ž
-42.18%92.52M
157.45%109.43M
-14.32%54.19M
1048.42%75.61M
517.83%160.03M
133.72%42.51M
113.76%63.24M
-81.57%6.58M
306.65%25.90M
38.35%-126.06M
-21018.65%-459.79M
392.19%35.73M
-146.61%-12.53M
-1177.36%-204.48M
35.76%2.20M
-73.51%7.26M
97.50%26.89M
433.15%18.98M
124.43%1.62M
-9.45%27.41M
์ˆœ์žฌ๋ฌดํ™œ๋™
124389.79%597.55M
4552.07%23.59M
3360.46%12.08M
7410.30%75.10M
-80.97%480.00K
-82.55%507.00K
-99.94%349.00K
431.91%1.00M
3508.11%2.52M
-98.91%2.91M
14384.63%606.04M
-98.25%188.00K
-840.00%-74.00K
16897.36%267.08M
183.58%4.18M
22770.21%10.75M
103.91%10.00K
-183.77%-1.59M
-196.44%-5.01M
-89.87%47.00K

์ž์ฃผ ๋ฌป๋Š” ์งˆ๋ฌธ

Viking Therapeutics Inc์˜ ์œ ๋™์ž์‚ฐ์€ ์–ผ๋งˆ์ธ๊ฐ€์š”?

๎™Œ
Viking Therapeutics Inc์˜ FY2025 ์‹ค์  ๋ณด๊ณ ์„œ์— ๋”ฐ๋ฅด๋ฉด, ์œ ๋™์ž์‚ฐ์€ 715.60M์ด๋ฉฐ, ์ „๋…„ ๋Œ€๋น„ ๋ณ€๋™์น˜๋Š” -21.12์ž…๋‹ˆ๋‹ค.

Viking Therapeutics Inc์˜ ์ด์ž์‚ฐ์€ ์–ผ๋งˆ์ธ๊ฐ€์š”?

๎™Œ
Viking Therapeutics Inc์˜ FY2025 ์‹ค์  ๋ณด๊ณ ์„œ์— ๋”ฐ๋ฅด๋ฉด, Viking Therapeutics Inc์˜ ์ด์ž์‚ฐ์€ 715.73M์ด๋ฉฐ, ์ „๋…„ ๋Œ€๋น„ ๋ณ€๋™์น˜๋Š” -21.20์ž…๋‹ˆ๋‹ค.

Viking Therapeutics Inc์˜ ์ด๋ถ€์ฑ„๋Š” ์–ผ๋งˆ์ธ๊ฐ€์š”?

๎™Œ
Viking Therapeutics Inc์˜ FY2025 ์‹ค์  ๋ณด๊ณ ์„œ์— ๋”ฐ๋ฅด๋ฉด, Viking Therapeutics Inc์˜ ์ด๋ถ€์ฑ„๋Š” 76.67M์ด๋ฉฐ, ์ „๋…„ ๋Œ€๋น„ ๋ณ€๋™์น˜๋Š” 173.39์ž…๋‹ˆ๋‹ค.

Viking Therapeutics Inc์˜ ์ด์ž๋ณธ์€ ์–ผ๋งˆ์ธ๊ฐ€์š”?

๎™Œ
Viking Therapeutics Inc์˜ FY2025 ์‹ค์  ๋ณด๊ณ ์„œ์— ๋”ฐ๋ฅด๋ฉด, Viking Therapeutics Inc์˜ ์ด์ž๋ณธ์€ 639.06M์ด๋ฉฐ, ์ „๋…„ ๋Œ€๋น„ ๋ณ€๋™์น˜๋Š” -27.40์ž…๋‹ˆ๋‹ค.

Viking Therapeutics Inc์˜ ์ˆœ์˜์—…์†Œ๋“์€ ์–ผ๋งˆ์ธ๊ฐ€์š”?

๎™Œ
Viking Therapeutics Inc์˜ FY2025 ์‹ค์  ๋ณด๊ณ ์„œ์— ๋”ฐ๋ฅด๋ฉด, Viking Therapeutics Inc์˜ ์ˆœ์˜์—…์†Œ๋“์€ -393.34M์ด๋ฉฐ, ์ „๋…„ ๋Œ€๋น„ ๋ณ€๋™์น˜๋Š” -160.63์ž…๋‹ˆ๋‹ค.

Viking Therapeutics Inc์˜ ์ˆœํˆฌ์ž๋Š” ์–ผ๋งˆ์ธ๊ฐ€์š”?

๎™Œ
Viking Therapeutics Inc์˜ FY2025 ์‹ค์  ๋ณด๊ณ ์„œ์— ๋”ฐ๋ฅด๋ฉด, Viking Therapeutics Inc์˜ ์ˆœํˆฌ์ž๋Š” 341.39M์ด๋ฉฐ, ์ „๋…„ ๋Œ€๋น„ ๋ณ€๋™์น˜๋Š” 161.69์ž…๋‹ˆ๋‹ค.

Viking Therapeutics Inc์˜ ์ˆœ์ž๊ธˆ์กฐ๋‹ฌ์€ ์–ผ๋งˆ์ธ๊ฐ€์š”?

๎™Œ
Viking Therapeutics Inc์˜ FY2025 ์‹ค์  ๋ณด๊ณ ์„œ์— ๋”ฐ๋ฅด๋ฉด, Viking Therapeutics Inc์˜ ์ˆœ์ž๊ธˆ์กฐ๋‹ฌ์€ 76.44M์ด๋ฉฐ, ์ „๋…„ ๋Œ€๋น„ ๋ณ€๋™์น˜๋Š” -87.52์ž…๋‹ˆ๋‹ค.

Viking Therapeutics Inc์˜ ์ฃผ๋‹น์ˆœ์ด์ต(EPS)์€ ์–ผ๋งˆ์ธ๊ฐ€์š”?

๎™Œ
Viking Therapeutics Inc์˜ FY2025 ์‹ค์  ๋ณด๊ณ ์„œ์— ๋”ฐ๋ฅด๋ฉด, ์ฃผ๋‹น์ˆœ์ด์ต(EPS)์€ -3.19์ด๋ฉฐ, ์ „๋…„ ๋Œ€๋น„ ๋ณ€๋™์น˜๋Š” -216.52์ž…๋‹ˆ๋‹ค.

Viking Therapeutics Inc์˜ ์ˆœ์ด์ต์€ ์–ผ๋งˆ์ธ๊ฐ€์š”?

๎™Œ
Viking Therapeutics Inc์˜ FY2025 ์‹ค์  ๋ณด๊ณ ์„œ์— ๋”ฐ๋ฅด๋ฉด, ์ˆœ์ด์ต์€ -359.64M์ด๋ฉฐ, ์ „๋…„ ๋Œ€๋น„ ๋ณ€๋™์น˜๋Š” -227.05์ž…๋‹ˆ๋‹ค.

Viking Therapeutics Inc์˜ ์ž๊ธฐ์ž๋ณธ์ด์ต๋ฅ (ROE)์€ ์–ผ๋งˆ์ธ๊ฐ€์š”?

๎™Œ
Viking Therapeutics Inc์˜ FY2025 ์‹ค์  ๋ณด๊ณ ์„œ์— ๋”ฐ๋ฅด๋ฉด, ์ž๊ธฐ์ž๋ณธ์ด์ต๋ฅ (ROE)์€ -47.34์ด๋ฉฐ, ์ „๋…„ ๋Œ€๋น„ ๋ณ€๋™์น˜๋Š” -164.49์ž…๋‹ˆ๋‹ค.

Viking Therapeutics Inc์˜ ์ด์ž์‚ฐ์ด์ต๋ฅ (ROA)์€ ์–ผ๋งˆ์ธ๊ฐ€์š”?

๎™Œ
Viking Therapeutics Inc์˜ FY2025 ์‹ค์  ๋ณด๊ณ ์„œ์— ๋”ฐ๋ฅด๋ฉด, ์ด์ž์‚ฐ์ด์ต๋ฅ (ROA)์€ -44.29์ด๋ฉฐ, ์ „๋…„ ๋Œ€๋น„ ๋ณ€๋™์น˜๋Š” -157.13์ž…๋‹ˆ๋‹ค.

Viking Therapeutics Inc์˜ ์˜์—…์ด์ต์€ ์–ผ๋งˆ์ธ๊ฐ€์š”?

๎™Œ
Viking Therapeutics Inc์˜ FY2025 ์‹ค์  ๋ณด๊ณ ์„œ์— ๋”ฐ๋ฅด๋ฉด, ์˜์—…์ด์ต์€ -393.34M์ด๋ฉฐ, ์ „๋…„ ๋Œ€๋น„ ๋ณ€๋™์น˜๋Š” -160.63์ž…๋‹ˆ๋‹ค.
tradingkey.logo
์œ„ํ—˜ ๊ฒฝ๊ณ : ์ €ํฌ ์›น์‚ฌ์ดํŠธ์™€ ๋ชจ๋ฐ”์ผ ์•ฑ์€ ํŠน์ • ํˆฌ์ž ์ƒํ’ˆ์— ๋Œ€ํ•œ ์ผ๋ฐ˜์ ์ธ ์ •๋ณด๋งŒ์„ ์ œ๊ณตํ•ฉ๋‹ˆ๋‹ค. Finsights๋Š” ์žฌ์ •์  ์กฐ์–ธ์ด๋‚˜ ํˆฌ์ž ์ƒํ’ˆ์— ๋Œ€ํ•œ ์ถ”์ฒœ์„ ์ œ๊ณตํ•˜์ง€ ์•Š์œผ๋ฉฐ, ์ด๋Ÿฌํ•œ ์ •๋ณด ์ œ๊ณต์ด Finsights๊ฐ€ ๊ธˆ์œต ์กฐ์–ธ์ด๋‚˜ ์ถ”์ฒœ์„ ์ œ๊ณตํ•˜๋Š” ๊ฒƒ์œผ๋กœ ํ•ด์„๋˜์–ด์„œ๋Š” ์•ˆ ๋ฉ๋‹ˆ๋‹ค.
ํˆฌ์ž ์ƒํ’ˆ์€ ํˆฌ์ž ์›๊ธˆ ์†์‹ค์„ ํฌํ•จํ•œ ์ƒ๋‹นํ•œ ํˆฌ์ž ์œ„ํ—˜์— ๋…ธ์ถœ๋˜์–ด ์žˆ์œผ๋ฉฐ, ๋ชจ๋“  ์‚ฌ๋žŒ์—๊ฒŒ ์ ํ•ฉํ•˜์ง€ ์•Š์„ ์ˆ˜ ์žˆ์Šต๋‹ˆ๋‹ค. ํˆฌ์ž ์ƒํ’ˆ์˜ ๊ณผ๊ฑฐ ์„ฑ๊ณผ๋Š” ๋ฏธ๋ž˜ ์„ฑ๊ณผ๋ฅผ ๋ณด์žฅํ•˜์ง€ ์•Š์Šต๋‹ˆ๋‹ค.
Finsights๋Š” ์ œ3์ž ๊ด‘๊ณ ์ฃผ๋‚˜ ์ œํœด์‚ฌ๊ฐ€ ์ €ํฌ ์›น์‚ฌ์ดํŠธ๋‚˜ ๋ชจ๋ฐ”์ผ ์•ฑ ๋˜๋Š” ๊ทธ ์ผ๋ถ€์— ๊ด‘๊ณ ๋ฅผ ๊ฒŒ์žฌํ•˜๊ฑฐ๋‚˜ ์ „๋‹ฌํ•  ์ˆ˜ ์žˆ๋„๋ก ํ—ˆ์šฉํ•  ์ˆ˜ ์žˆ์œผ๋ฉฐ, ์‚ฌ์šฉ์ž๊ฐ€ ๊ด‘๊ณ ์™€ ์ƒํ˜ธ์ž‘์šฉํ•˜๋Š” ๋ฐฉ์‹์— ๋”ฐ๋ผ ์ด๋“ค๋กœ๋ถ€ํ„ฐ ๋ณด์ƒ์„ ๋ฐ›์„ ์ˆ˜ ์žˆ์Šต๋‹ˆ๋‹ค.
ยฉ ์ €์ž‘๊ถŒ: FINSIGHTS MEDIA PTE. LTD. ๋ชจ๋“  ๊ถŒ๋ฆฌ ๋ณด์œ